[PDF][PDF] Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jérémie Calais
Medicine, and Jérémie Calais, MD, MSc, his colleague at UCLA, talked with Michael
Hofman, MBSS, about success and innovation in clinical trial development. Hofman is a …
Hofman, MBSS, about success and innovation in clinical trial development. Hofman is a …
Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group
Introduction The Prostate Cancer Foundation (PCF) convened a PSMA‐Directed
Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine …
Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine …
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging
HL Cho, S Perni, AV D'Amico, K Yamoah… - Prostate Cancer and …, 2023 - nature.com
Prostate-specific membrane antigen (PSMA)-targeted scans represent an opportunity to
improve prostate cancer management. Existing imaging modalities in prostate cancer …
improve prostate cancer management. Existing imaging modalities in prostate cancer …
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
Abstract Introduction The Prostate Cancer Foundation (PCF) convened a PCF prostate‐
specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 …
specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 …
Clinical trials of prostate-specific membrane antigen radiopharmaceutical therapy
H Jadvar, PM Colletti - Journal of Nuclear Medicine Technology, 2023 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph
for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (68Ga-PSMA …
for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (68Ga-PSMA …
[PDF][PDF] Nuclear medicine beyond VISION
WP Fendler, K Herrmann, M Eiber - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
In March 2021, Novartis announced a positive result for both primary endpoints of the
randomized phase III VISION study on 177Lu-PSMA-617 radioligand therapy (RLT). 177Lu …
randomized phase III VISION study on 177Lu-PSMA-617 radioligand therapy (RLT). 177Lu …
Considerations on integrating prostate-specific membrane antigen positron emission tomography imaging into clinical prostate cancer trials by National Clinical Trials …
PURPOSE As prostate-specific membrane antigen (PSMA) positron emission tomography
(PET) becomes increasingly available in the United States, the greater sensitivity of the …
(PET) becomes increasingly available in the United States, the greater sensitivity of the …
[PDF][PDF] We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer
WP Fendler, J Calais - European Urology Focus, 2021 - researchgate.net
Prostate cancer management is guided by a growing array of clinical, biochemical, imaging,
and genetic vectors. Prostate-specific membrane antigen (PSMA)-directed small …
and genetic vectors. Prostate-specific membrane antigen (PSMA)-directed small …
[PDF][PDF] Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective …
O Sartor - Journal of Nuclear Medicine, 2022 - Soc Nuclear Med
Selection of patients for treatment with prostate-specific membrane antigen (PSMA) targeted
therapy is somewhat controversial. There are those that have suggested that no selection is …
therapy is somewhat controversial. There are those that have suggested that no selection is …
Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics
Prostate-specific membrane antigen (PSMA) is of considerable interest as a target for
diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has …
diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has …